We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Edwards Lifesciences (EW - Free Report) closed the most recent trading day at $97.45, moving -1.99% from the previous trading session. This move lagged the S&P 500's daily loss of 0.84%. Elsewhere, the Dow lost 0.69%, while the tech-heavy Nasdaq lost 0.07%.
Heading into today, shares of the medical device maker had gained 13.26% over the past month, outpacing the Medical sector's gain of 6.79% and the S&P 500's gain of 2.02% in that time.
Investors will be hoping for strength from Edwards Lifesciences as it approaches its next earnings release, which is expected to be July 28, 2022. The company is expected to report EPS of $0.64, unchanged from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.4 billion, up 1.97% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.57 per share and revenue of $5.72 billion. These totals would mark changes of +15.77% and +9.29%, respectively, from last year.
Any recent changes to analyst estimates for Edwards Lifesciences should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.07% lower within the past month. Edwards Lifesciences is currently sporting a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Edwards Lifesciences has a Forward P/E ratio of 38.73 right now. For comparison, its industry has an average Forward P/E of 27.75, which means Edwards Lifesciences is trading at a premium to the group.
It is also worth noting that EW currently has a PEG ratio of 2.87. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 1.83 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 90, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
Edwards Lifesciences (EW - Free Report) closed the most recent trading day at $97.45, moving -1.99% from the previous trading session. This move lagged the S&P 500's daily loss of 0.84%. Elsewhere, the Dow lost 0.69%, while the tech-heavy Nasdaq lost 0.07%.
Heading into today, shares of the medical device maker had gained 13.26% over the past month, outpacing the Medical sector's gain of 6.79% and the S&P 500's gain of 2.02% in that time.
Investors will be hoping for strength from Edwards Lifesciences as it approaches its next earnings release, which is expected to be July 28, 2022. The company is expected to report EPS of $0.64, unchanged from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.4 billion, up 1.97% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.57 per share and revenue of $5.72 billion. These totals would mark changes of +15.77% and +9.29%, respectively, from last year.
Any recent changes to analyst estimates for Edwards Lifesciences should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.07% lower within the past month. Edwards Lifesciences is currently sporting a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Edwards Lifesciences has a Forward P/E ratio of 38.73 right now. For comparison, its industry has an average Forward P/E of 27.75, which means Edwards Lifesciences is trading at a premium to the group.
It is also worth noting that EW currently has a PEG ratio of 2.87. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 1.83 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 90, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.